NeoGenomics Raises Full-Year Guidance Following Strong Q2 Performance
NeoGenomics reported second-quarter revenue growth of 11% year over year, reaching $201.7 million, driven by a 14% increase in clinical revenue and strong performance from next-generation sequencing (NGS) services. The company raised its full-year revenue guidance to between $802 million and $806 million and adjusted EBITDA guidance to $56–$58 million. NGS revenue grew by 26% year over year, representing about one-third of clinical revenue, fueled by broader genomic profiling demand. Adjusted gross margin expanded to 48.1%, while non-clinical revenue declined by 15%. The company is investing in commercial expansion and MRD testing initiatives. CEO Tony Zook highlighted the strategic shift toward higher-value solid-tumor therapy selection and MRD testing, which supports NGS growth and margin improvement. CFO Abhishek Jain noted that average revenue per test (AUP) increased due to managed-care pricing gains and improved reimbursement.
Tickers: $NEO
Topics: clinical testing EBITDA growth guidance revision NGS (next-generation sequencing)